Page last updated: 2024-11-05

disopyramide phosphate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Disopyramide phosphate is an antiarrhythmic drug that is used to treat ventricular tachycardia and other types of arrhythmias. It is a class IA antiarrhythmic agent, meaning that it blocks sodium channels in the heart, which helps to slow the heart rate and reduce the risk of arrhythmias. Disopyramide phosphate is also a potassium channel blocker, which can help to prolong the action potential duration and increase the refractory period. The synthesis of disopyramide phosphate involves the reaction of disopyramide with phosphoric acid. It is administered orally and is available in immediate-release and sustained-release formulations. Disopyramide phosphate has been studied extensively for its effects on cardiac rhythm and electrophysiology. Research has shown that it is effective in treating a variety of arrhythmias, but it can also have serious side effects, such as heart failure and hypotension. Disopyramide phosphate is generally considered to be a safe and effective drug when used appropriately. However, it is important to be aware of its potential side effects and to use it only under the supervision of a healthcare professional. Disopyramide phosphate is important because it can help to prevent life-threatening arrhythmias. It is also an important research tool for studying cardiac electrophysiology. '

Cross-References

ID SourceID
PubMed CID30928
CHEMBL ID1201020
CHEBI ID4658
SCHEMBL ID41810
MeSH IDM0330465

Synonyms (104)

Synonym
disopyramid phosphate
MLS000028431
EU-0100411
disopyramide phosphate salt
rythmodan
alpha-(2-(diisopropylamino)ethyl)-alpha-phenyl-2-pyridineacetamide phosphate (1:1)
2-pyridineacetamide, alpha-(2-(diisopropylamino)ethyl)-alpha-phenyl-, phosphate
2-(1-(ammoniocarbonyl)-3-(diisopropylammonio)-1-phenylpropyl)pyridinium phosphate
2-pyridineacetamide, alpha-(2-(bis(1-methylethyl)amino)ethyl)-alpha-phenyl-, phosphate
einecs 244-756-1
sc 13957
sc 7031 phosphate
(+-)-alpha-(2-(diisopropylamino)ethyl)-alpha-phenyl-2-pyridineacetamide phosphate (1:1)
2-pyridineacetamide, alpha-(2-(bis(1-methylethyl)amino)ethyl)-alpha-phenyl-, (+-)-, phosphate (1:1)
norpace cr
2-pyridineacetamide, alpha-(2-(bis(1-methylethyl)amino)ethyl)-alpha-phenyl-, phosphate (1:1)
alpha-(2-diisopropylaminoethyl)-alpha-phenyl-2-pyridineacetamide phosphate
sc-13957
disopyramide phosphate (1:1)
22059-60-5
C07740
disopyramide phosphate
disopyramide phosphate (jan/usp)
D00637
norpace (tn)
NCGC00093836-03
NCGC00093836-02
norpace
smr000058438
SPECTRUM1500261
NCGC00093836-01
NCGC00093836-04
HMS2094K15
D 6035
sc-7031 phosphate
dirythmin sa
nsc-756744
diso-duriles
CHEMBL1201020
chebi:4658 ,
HMS501I11
HMS1920I14
HMS3261C04
HMS3259J21
pharmakon1600-01500261
nsc756744
HMS2234B16
CCG-40209
nsc 756744
unii-n6bom1935w
disopyramide phosphate [usan:usp:ban:jan]
n6bom1935w ,
FT-0630479
LP00411
HMS3369L05
79190-73-1
2-pyridineacetamide, .alpha.-(2-(bis(1-methylethyl)amino)ethyl)-.alpha.-phenyl-, (+/-)-, phosphate (1:1)
disopyramide phosphate [usan]
4-diisopropylamino-2-phenyl-2-(2-pyridyl)butyramide phosphate
(+/-)-.alpha.-(2-(diisopropylamino)ethyl)-.alpha.-phenyl-2-pyridineacetamide phosphate (1:1)
disopyramide phosphate [usp monograph]
disopyramide phosphate [mart.]
disopyramide phosphate [jan]
disopyramide phosphate [ep monograph]
disopyramide phosphate [orange book]
disopyramide phosphate [vandf]
disopyramide phosphate [who-dd]
disopyramide phosphate [usp-rs]
disopyramide phosphate [mi]
NC00683
SCHEMBL41810
NCGC00261096-01
tox21_500411
4-(diisopropylamino)-2-phenyl-2-(2-pyridyl)butanamide
sr-01000003039
disopyramide phosphate, united states pharmacopeia (usp) reference standard
disopyramide phosphate, european pharmacopoeia (ep) reference standard
HMS3652M20
SR-01000003039-6
SR-01000003039-2
SW196836-4
SW196836-3
(r)-4-(diisopropylamino)-2-phenyl-2-(pyridin-2-yl)butanamide phosphate
S4143
DTXSID30944685
Q27106430
4-[di(propan-2-yl)amino]-2-phenyl-2-pyridin-2-ylbutanamide;phosphoric acid
HMS3885J07
sc 7031 (phosphate)
22059-60-5 (phosphate)
4-(diisopropylamino)-2-phenyl-2-(pyridin-2-yl)butanamide phosphate
disopyramidephosphate
XAA05960
disopyramide (phosphate)
HY-12533A
AKOS040744844
disopyramide phosphate (usp monograph)
alpha-(2-(diisopropylamino)ethyl)-alpha-phenyl-2-pyridineacetamide phosphate(1:1)
disopyramide phosphate (ep monograph)
2-pyridineacetamide, alpha-(2-(bis(1-methylethyl)amino)ethyl)-alpha-phenyl-, (+/-)-, phosphate (1:1)
disopyramide phosphate (mart.)
disopyramide phosphate (usp-rs)
disopyramide phosphate (usan:usp:ban:jan)
(+/-)-alpha-(2-(diisopropylamino)ethyl)-alpha-phenyl-2-pyridineacetamide phosphate (1:1)

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" An understanding of structure-activity relationships (SARs) of chemicals can make a significant contribution to the identification of potential toxic effects early in the drug development process and aid in avoiding such problems."( Developing structure-activity relationships for the prediction of hepatotoxicity.
Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ, 2010
)
0.36
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
organoammonium phosphate
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (6)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASEHomo sapiens (human)Potency0.00350.003245.467312,589.2998AID2517
IDH1Homo sapiens (human)Potency1.29950.005210.865235.4813AID686970
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency56.23410.035520.977089.1251AID504332
chromobox protein homolog 1Homo sapiens (human)Potency89.12510.006026.168889.1251AID540317
potassium voltage-gated channel subfamily H member 2 isoform dHomo sapiens (human)Potency5.01190.01789.637444.6684AID588834
gemininHomo sapiens (human)Potency0.00460.004611.374133.4983AID624297
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (35)

Assay IDTitleYearJournalArticle
AID1347057CD47-SIRPalpha protein protein interaction - LANCE assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347059CD47-SIRPalpha protein protein interaction - Alpha assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347410qHTS for inhibitors of adenylyl cyclases using a fission yeast platform: a pilot screen against the NCATS LOPAC library2019Cellular signalling, 08, Volume: 60A fission yeast platform for heterologous expression of mammalian adenylyl cyclases and high throughput screening.
AID1347405qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS LOPAC collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347058CD47-SIRPalpha protein protein interaction - HTRF assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347151Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1132566Antiarrhythmic activity in iv dosed mongrel dog assessed as reduction in ouabain-induced ventricular arrhythmia by electrocardiographic analysis1978Journal of medicinal chemistry, Apr, Volume: 21, Issue:4
Synthesis and antiarrhythmic activity of 2-dialkylaminoalkyl-9-phenyl-1H-indeno[2,1-c]pyridine derivatives.
AID1132568Antiarrhythmic activity in mongrel dog Harris two-stage coronary ligation model assessed as reduction in ectopic beats by electrocardiographic analysis1978Journal of medicinal chemistry, Apr, Volume: 21, Issue:4
Synthesis and antiarrhythmic activity of 2-dialkylaminoalkyl-9-phenyl-1H-indeno[2,1-c]pyridine derivatives.
AID1132569Antiarrhythmic activity in mongrel dog Harris two-stage coronary ligation model assessed as reduction in ectopic beats measured as duration of action at MED by electrocardiographic analysis1978Journal of medicinal chemistry, Apr, Volume: 21, Issue:4
Synthesis and antiarrhythmic activity of 2-dialkylaminoalkyl-9-phenyl-1H-indeno[2,1-c]pyridine derivatives.
AID588210Human drug-induced liver injury (DILI) modelling dataset from Ekins et al2010Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 38, Issue:12
A predictive ligand-based Bayesian model for human drug-induced liver injury.
AID524794Antiplasmodial activity against Plasmodium falciparum GB4 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID521220Inhibition of neurosphere proliferation of mouse neural precursor cells by MTT assay2007Nature chemical biology, May, Volume: 3, Issue:5
Chemical genetics reveals a complex functional ground state of neural stem cells.
AID588209Literature-mined public compounds from Greene et al multi-species hepatotoxicity modelling dataset2010Chemical research in toxicology, Jul-19, Volume: 23, Issue:7
Developing structure-activity relationships for the prediction of hepatotoxicity.
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID1132567Antiarrhythmic activity in iv dosed mongrel dog assessed as reduction in ouabain-induced ventricular arrhythmia measured as duration of action at MED by electrocardiographic analysis1978Journal of medicinal chemistry, Apr, Volume: 21, Issue:4
Synthesis and antiarrhythmic activity of 2-dialkylaminoalkyl-9-phenyl-1H-indeno[2,1-c]pyridine derivatives.
AID524796Antiplasmodial activity against Plasmodium falciparum W2 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (20)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (5.00)18.7374
1990's0 (0.00)18.2507
2000's3 (15.00)29.6817
2010's12 (60.00)24.3611
2020's4 (20.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 42.96

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index42.96 (24.57)
Research Supply Index3.04 (2.92)
Research Growth Index4.29 (4.65)
Search Engine Demand Index60.29 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (42.96)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (5.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other19 (95.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]